InspireMD, Inc. (NYSEMKT:NSPR) Files An 8-K Other Events
Item 8.01 Other Events.
On May 15, 2017, InspireMD, Inc. announced signing of
distribution agreements for CGuard EPS and the MGuard Prime EPS
with Dispositivos Medicos E.I.R.L., as well as Cardiobene S.A.,
the medical distributors in Peru and Ecuador, respectively. A
copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is hereby incorporated by
reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Description | |
| 99.1 | Press release dated May 15, 2017 |
About InspireMD, Inc. (NYSEMKT:NSPR)
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. InspireMD, Inc. (NYSEMKT:NSPR) Recent Trading Information
InspireMD, Inc. (NYSEMKT:NSPR) closed its last trading session down -0.025 at 0.555 with 305,462 shares trading hands.
